Amphastar
FDA rejects Amphastar’s application for NDA for intranasal overdose treatment
February 21, 2017Research and Development Amphastar, FDA
Amphastar has received a Complete Response Letter (CRL) for its New Drug Application (NDA) for an intranasal version of Naloxone, …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
